The Kim Lab – where genomics meets cancer biology
We are focused on understanding the genetic events involved in the initiation and progression of renal cell carcinoma (RCC) and bladder cancer as well as how they affect the tumor immune microenvironment. Leveraging NextGeneration sequencing (NGS) and spatial transcriptomics of primary human tumors and the faithfulness of genetically engineered murine (GEM) models our goal is to identify the critical genomic changes that are drivers of RCC and bladder cancer with an eye towards identifying therapeutic vulnerabilities.
We are a highly collaborative and multidisciplinary group that believes in team science and are committed to equality in science and medicine.
“I never lose. Either I win or learn.”
– Nelson Mandela
About the PI
William Y. Kim, MD, is the Rush S. Dickson Distinguished Professor of Medicine, Genetics, and Pharmacology at UNC-Chapel Hill and is a laboratory-based physician-scientist.
Dr. Kim is part of the Urologic Oncology Program and cares for patients with genitourinary malignancies.
Dr. Kim is the Co-Leader of the GU Oncology Research Program, co-Leader of the Cancer Genetics Program.